Tagged Articles

tests 22 articles

Direct-to-consumer advertising likely inflating demand for testosterone drugs, new study finds

Testosterone replacement therapy for men increased in the U.S. and the U.K. between 2000 and 2011, but whereas supplementation rates quadrupled in the U.S. during that time, they rose just 30 percent in the U.K., according to a new study published in the Journal of Clinical Endocrinology & Metabolism. One likely explanation for the drastically different rates of low-testosterone treatment in the U.S. compared to the U.K. is the prevalence of direct-to-consumer (DTC) advertising in the U.S. DTC advertising has been legal in the U.S. since 1982, but few drug makers took that marketing approach due to requirements about disclosing ... Read More

Five years of Actos likely caused plaintiff’s terminal bladder cancer, doctor testifies

A University of Chicago Medical Center urologist told a Los Angeles jury last week that Takeda Pharmaceuticals’ type-2 diabetes drug Actos was “the most substantial causative factor” in a California man’s development of terminal bladder cancer. The doctor’s testimony was part of the first product liability case against Takeda to go to trial over injuries allegedly caused by the blockbuster drug. Plaintiff Jack Cooper, a 79-year-old San Diego area resident, sued Japan-based Takeda after taking Actos for a five-year period from 2006 to 2011. His lawsuit against Takeda was selected as the first of more than 3,000 similar cases to ... Read More

New Actos lawsuit accuses Takeda of inadequately stating, concealing drug’s risks

A Minnesota man has filed a lawsuit against Takeda Pharmaceuticals and Eli Lilly and Company for injuries he allegedly received as a result of taking the diabetes drug Actos (pioglitazone). The plaintiff, one of the latest to join the Actos litigation consolidated in federal court in Lafayette, Louisiana, claims the type 2 diabetes drug caused him to develop bladder cancer. He seeks damages for permanent injuries, severe mental and physical pain and suffering, and economic losses related to his medical expenses and the costs of maintaining a change in lifestyle brought about by his injuries. Like many plaintiffs who allege ... Read More

First Actos bladder-cancer claim against Takeda headed to trial in February

The first lawsuit against Takeda Pharmaceuticals and related companies over Actos injuries will be heard February 19 in Los Angeles Superior Court. In that case, Mississippi resident Jack Cooper alleges that he developed bladder cancer as a result of taking Actos to treat his type 2 diabetes. Mr. Cooper filed his lawsuit in California, where Japan-based Takeda keeps its North American headquarters. Because it will be the first Actos case to go to trial, Mr. Cooper’s lawsuit will serve as a bellwether for potentially thousands of other such cases filed throughout the country. A recent Business Week report estimates the number of ... Read More

Court overturns FDA’s decision barring Watson from making generic Actos

Prescriptions of Takeda Pharmaceutical’s blockbuster diabetes drug Actos (pioglitazone) have plummeted since a number of clinical studies linked the drug to a significantly higher risk of bladder cancer in patients, but those safety concerns haven’t dissuaded a group of other drug makers from fighting over the rights to make their own generic versions as Takeda’s Actos patent expires. On Monday, U.S. District Judge Amy Berman Jackson in Washington overturned the U.S. Food and Drug Administration’s (FDA) decision to bar Watson Pharmaceuticals from joining a period of shared exclusivity the agency grants to companies that are first to file for the ... Read More

Several patients sue Takeda over Actos injuries, cancer in Los Angeles

Fourteen people have filed a personal injury lawsuit against Takeda Pharmaceuticals alleging the its diabetes drug Actos (pioglitazone) caused them to develop bladder cancer. The lawsuit, filed in Los Angeles Superior Court, also names Takeda’s subsidiaries and Eli Lilly, which helped the Japan-based drugmaker market the blockbuster drug. According to the plaintiffs’ lawyers, the former Actos users claim the drug promoted the growth of bladder cancer and a number of related complications, including “permanent, severe and debilitating injuries, pain and suffering, and emotional distress.” As a result of the injuries allegedly brought about by Takeda’s “negligence, fraud and malice,” the ... Read More

Takeda faces Actos class-action in Quebec

MONTREAL, QUEBEC–A group of Actos patients from Quebec, Canada have filed a class action lawsuit against Takeda Pharmaceuticals and its affiliate Eli Lilly in an effort to collect damages for injuries they allege were brought about by the blockbuster diabetes drug. The latest Canadian lawsuit asserts that Japan-based Takeda and Indiana-based Eli Lilly knew about but failed to disclose critical safety information that the popular drug, used to treat patients with type 2 diabetes, promotes the development of bladder cancer. The Quebec patients involved in the new class action developed bladder cancer as a result of taking Actos, the lawsuit ... Read More

Researchers to test Actos as potential Alzheimer’s treatment

Takeda’s controversial diabetes drug Actos could soon be used to treat patients at high risk of developing Alzheimer’s disease, opening the drug to an entirely new customer base beyond diabetic patients. Previous research has established a link between decreased glucose utilization in the brain and Alzheimer’s disease. Actos (pioglitazone) is used to regulate glucose (blood sugar) in the body by making cells more sensitive to insulin – a natural hormone that stabilizes blood sugar levels. Only recently have researchers discovered that Actos taken by diabetic patients reaches the brain. Expanding on that knowledge, researchers with Takeda and Zinfandel Pharmaceuticals used ... Read More

Vehicular heatstroke warning devices ineffective, NHTSA warns

Safety products designed to alert parents about children accidentally left in dangerously hot vehicles are unreliable, federal safety regulators said Monday. The National Highway Traffic Safety Administration (NHTSA) made the announcement amidst a push to raise awareness of auto safety concerns affecting children, including efforts aimed at preventing heatstroke death and injuries in children left in unattended vehicles. According to the agency, 527 children have died from heatstroke injuries they received by being locked in hot vehicles – about 38 deaths per year on average. Heatstroke is the leading non-crash, vehicle-related cause of death for children. NHTSA also warned that ... Read More

Takeda failed to warn about Actos bladder cancer risk, Lousiana plaintiff alleges

Actos remained on the market for more than a decade before consumers learned that prolonged use of the popular diabetes drug could elevate the risk of developing bladder cancer in patients. Now several former Actos users battling bladder cancer believe they could have made a better choice had Takeda Pharmaceutical Company warned patients of the drug’s apparent link to bladder cancer. One of the latest plaintiffs to file a lawsuit against Takeda and Eli Lily and Co., which partnered with the Japanese company to push the drug, is a Louisiana man who alleges Actos caused him to develop bladder cancer ... Read More